Tapentadol
Nucynta (tapentadol) is a small molecule pharmaceutical. Tapentadol was first approved as Nucynta on 2008-11-20. It is used to treat pain in the USA. The pharmaceutical is active against mu-type opioid receptor and sodium-dependent noradrenaline transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Nucynta (discontinued: Nucynta)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tapentadol hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NUCYNTA | Collegium Pharmaceutical | N-022304 RX | 2008-11-20 | 3 products, RLD, RS |
| NUCYNTA ER | Collegium Pharmaceutical | N-200533 RX | 2011-08-25 | 5 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nucynta | New Drug Application | 2023-12-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TAPENTADOL HYDROCHLORIDE, NUCYNTA, COLLEGIUM PHARM INC | |||
| 2026-07-03 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
79 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 1 | 6 | 15 | 1 | 1 | 23 |
| Chronic pain | D059350 | — | — | — | 3 | 9 | 1 | 2 | 15 |
| Low back pain | D017116 | — | M54.5 | — | 2 | 8 | 3 | — | 13 |
| Back pain | D001416 | — | M54 | — | 2 | 9 | 2 | — | 13 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 2 | 9 | 1 | — | 12 |
| Postoperative pain | D010149 | — | G89.18 | — | 4 | 2 | 3 | 2 | 11 |
| Acute pain | D059787 | — | R52 | — | 1 | 8 | 1 | 1 | 11 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 1 | 1 | 3 | 2 | 7 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 2 | 3 | 1 | — | 6 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | 3 | 1 | — | 4 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | 5 | — | 1 | 7 |
| Cancer pain | D000072716 | — | G89.3 | — | 1 | 4 | — | 2 | 7 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 1 | 3 | — | — | 4 |
| Arthralgia | D018771 | — | M25.5 | — | — | 4 | — | — | 4 |
| Hallux valgus | D006215 | — | — | — | — | 4 | — | — | 4 |
| Bunion | D000071378 | — | M21.61 | — | 1 | 3 | — | — | 4 |
| Joint diseases | D007592 | — | M12.9 | — | — | 2 | — | — | 2 |
| Pain measurement | D010147 | — | — | — | — | 2 | — | — | 2 |
| Nociceptive pain | D059226 | — | — | — | — | 1 | — | — | 1 |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | — | 1 | — | — | 1 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postherpetic neuralgia | D051474 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Pharmacokinetics | D010599 | — | — | 4 | — | — | — | — | 4 |
| Hyperalgesia | D006930 | — | — | 1 | — | — | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 2 | 2 |
| Analgesia | D000698 | — | — | — | — | — | — | 2 | 2 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
| Narcotic-related disorders | D000079524 | — | — | — | — | — | — | 1 | 1 |
| Immunity | D007109 | — | — | — | — | — | — | 1 | 1 |
| Substance abuse detection | D015813 | — | — | — | — | — | — | 1 | 1 |
| Procedural pain | D000073818 | — | — | — | — | — | — | 1 | 1 |
| Walker-warburg syndrome | D058494 | Orphanet_899 | Q04.3 | — | — | — | — | 1 | 1 |
| Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
| Agnosia | D000377 | EFO_0007136 | F88 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tapentadol |
| INN | tapentadol |
| Description | Tapentadol is an alkylbenzene. |
| Classification | Small molecule |
| Drug class | analgesics (mixed opiate receptor agonists/antagonists) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C |
Identifiers
| PDB | — |
| CAS-ID | 175591-09-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201776 |
| ChEBI ID | — |
| PubChem CID | 9838022 |
| DrugBank | DB06204 |
| UNII ID | H8A007M585 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Nucynta – Assertio Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Nucynta – Assertio Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Nucynta – Collegium Pharmaceutical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Tapentadol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,725 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nucynta
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,771 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use